

Legal and Administrative Details

Financial statements

The financial statements comply with the Statement of Recommended Practice (SORP) – Accounting and Reporting by Charities as revised in 2005, the Charities Act (1993) and the Companies Act (1985).

Charity status

Cancer Research UK is registered in England and Wales as a charity, number 1089464, and as a company limited by guarantee, number 4325234. The Charity has a maximum permitted membership of 100. There are currently 80 Members, of which 17 are Trustees (pages 55 to 58). Each Member guarantees to contribute up to one pound sterling (£1) to the Charity's debts, liabilities and costs in the event of the Charity being wound up and for one year after ceasing to be a Member. Cancer Research UK is governed by its Memorandum and Articles of Association. Cancer Research UK also operates under the following names: Cancer Research UK Scotland, Cancer Research UK Cymru, Cancer Research UK Jersey, Cancer Research UK Guernsey and Cancer Research Northern Ireland.

Charity objects

The Charity's objects are to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of all forms of cancer, including the development of findings of research into the practical applications for the prevention, treatment and cure of cancer and in furtherance of that primary object, to provide information and raise public understanding of such matters.

Registered office

61 Lincoln's Inn Fields, London WC2A 3PX

Patron

Her Majesty The Queen

Joint Presidents

HRH The Duke of Gloucester KG GCVO

HRH Princess Alexandra The Hon Lady Ogilvy KG GCVO

Trustees

Chairman

David Newbigging OBE

Deputy Chairman

Dr Melanie Lee

Treasurer

Dr Keith Palmer

Council

Council's role is to set the Charity's strategic direction, monitor the delivery of the Charity's objectives, uphold its values and governance, and guide, advise and support the Chief Executive, who leads the Executive Board towards achieving the Charity's vision and purpose.

The Trustees who served during the year and as at 30 July 2008 are listed below along with brief biographies of those serving as at 30 July 2008. Trustees serve on six Council Committees, to which Council delegates certain authorities to act on the Charity's behalf in accordance with its governance policy. Their roles and responsibilities are clearly defined and each Committee regularly reviews its activity in line with its authority. The Chairman of Council is a member of all Council Committees except for the Audit Committee, which he may attend. In addition, advisory groups provide expert advice and guidance to the Executive Board of the Charity in their relevant areas of expertise. Trustee membership of these Committees and advisory groups is denoted as follows.

Council committees

-  AC Audit Committee
-  CC Chairman's Committee
-  CR Council Research Strategy Committee
-  FC Finance Committee
-  NG Nomination and Governance Committee
-  RC Remuneration Committee

Advisory committees

-  FM Fundraising and Supporter Marketing Advisory Committee
-  HR Human Resources Advisory Committee

David Newbigging OBE**Chairman**

CC Chair NG Chair CR FC RC

Mr Newbigging (b 1934) was appointed Chairman in November 2004, having been Deputy Chairman since March 2002. He is currently Chairman of Synesis Life Ltd, a Director of Cancer Research Technology and a Director of Wah Kwong Maritime Transport Holdings Limited in Hong Kong. He was Chairman of Talbot Holdings Limited until July 2007 and Chairman of Friends Provident plc until May 2005. He was a director of Merrill Lynch & Co Inc in New York from 1996 until April 2007, and was a director of PACCAR Inc in Bellevue, Washington from 1996 to 2006. His early career was spent in Asia where he worked for 30 years for the Jardine, Matheson Group of which he was Chairman and Chief Executive for nine years before relocating to the UK in 1984. In Hong Kong he was a member of the Executive and Legislative Councils and Chairman or Director of several publicly listed companies, including being Chairman of the Hong Kong Land Company and a Director of The Hong Kong and Shanghai Banking Corporation. Former appointments in the UK include Chairman of Rentokil Group plc, Equitas Holdings Limited and Thistle Hotels plc. His non-business interests include being a Trustee of National Crimebeat. He is a former Chairman of the Wiltshire Community Foundation. He was High Sheriff of Wiltshire in 2003/04 and was also Chairman of the Council of the Mission to Seafarers from 1993 to 2006.

Dr Melanie G Lee BSc DSc (Hon) FMedSci**Deputy Chairman from 13.09.07**

AC CR FC NG RC

Dr Melanie Lee (b 1958) studied as a postdoctoral scientist with the Cancer Research Campaign (CRC) and the Imperial Cancer Research Fund (ICRF). She is currently Executive Vice-President UCB, a leading global biopharmaceutical company where she is President NewMedicines. Dr Lee joined the Board of Imperial Cancer Research Technology Ltd (ICRT) in 2001 and, following the merger of ICRF and CRC, played a key role in the strategic planning of the business model for Cancer Research UK's technology transfer company, Cancer Research Technology Limited (CRT), and became its Chairman in 2003. She sits on the Scientific Advisory Board for The School of Biological Sciences at Cambridge University, is a member of the Biochemistry Society and the Genetics Society, and was elected a Fellow of the Academy of Sciences in 2003. Dr Lee received an Honorary Postdoctoral Degree from the University of York in 2004 and is a William Pitt Fellow of Pembroke College, Cambridge.

Professor Colin C Bird CBE FRSE

CR

Professor Bird (b 1938) is Chairman and Trustee/Director of onCore UK. He was formerly Dean of Medicine and Provost of Medicine and Veterinary Medicine at Edinburgh University and Professor of Pathology at Leeds and Edinburgh universities. He has longstanding interests in cancer research, both basic and clinical aspects, and has worked on these in several universities and research institutes in the UK and USA. He has served previously on the Medical Research Council's Research Boards and Grants Committees, the Cancer Research Campaign Scientific Advisory and other Committees and various national NHS Advisory Committees on Cancer. He is a Fellow of the Royal Colleges of Pathologists, Physicians and Surgeons and of the Academy of Medical Sciences.

Professor Sir Kenneth Calman KCB DL FRSE**Appointed 13.09.07**

CR

Sir Kenneth Calman (b 1941) is currently Chancellor of the University of Glasgow, a member of the Board of the British Library, Chairman of The National Cancer Research Institute, Chairman of the Glasgow Science Centre, and President of the Institute of Medical Ethics. He has recently been appointed Chair of the Commission approved by the Scottish Parliament to review devolution. He was Vice Chancellor at the University of Durham for almost nine years. While in Durham he was a member of the Regional Committee of the CBI and of the North East Chamber of Commerce. Before taking up his appointment at the University of Durham he was Chief Medical Officer at the Scottish Home and Health Department from 1989 and the Chief Medical Officer for England (1991-98). Sir Kenneth also served for many years as a prominent clinical professor and he is the author of many books on the care and treatment of cancer and on medical education. Sir Kenneth has served as Chairman of the Executive Board of the World Health Organisation and the European Environment and Health Committee. He is a Fellow of several academic and professional bodies including the Royal College of Physicians, the Royal College of Surgeons and the Royal Society of Edinburgh. In 1996 he became a Knight Commander of the Order of the Bath.

Council Committees**AC** Audit Committee**CC** Chairman's Committee**CR** Council Research Strategy Committee**FC** Finance Committee**NG** Nomination and Governance Committee**RC** Remuneration Committee**Advisory Committees****FM** Fundraising and Supporter Marketing
Advisory Committee**HR** Human Resources Advisory Committee**Dr Philip H M Campbell** BSc MSc PhD DSc FInstP FRAS**CR** **NG**

Dr Campbell (b 1951) is the Editor-in-Chief of Nature and of Nature publications. After a period of post-doctoral research in physics, he joined Nature in 1979, becoming Physical Sciences editor in 1982. He left Nature in 1988 to be the founding editor of Physics World. He is a Fellow of the Institute of Physics and a Fellow of the Royal Astronomical Society. He took up his present position in December 1995, and is also a member of the board of directors of the Nature Publishing Group. In a personal capacity, he has advised or collaborated with the Wellcome Trust, the US National Institutes of Health, the UK Office of Science and Technology and the European Commission on aspects of the life sciences and their impacts in society.

Sir James Crosby**Appointed 31.01.08****FC** **RC**

Sir James (b 1956) is the Deputy Chairman of the Financial Services Authority (FSA) (Director January 2004 to present, Deputy Chairman since December 2007), senior independent director of ITV plc (formerly Granada plc, November 2002 to present) and Compass Group plc (February 2007 to present). He is also a member of the European Advisory Board of Bridgepoint Capital (September 2006 to present), a member of the Finance Committee of the Delegacy of Oxford University Press (September 2006 to present) and Chairman of the Government's Working Group on Mortgage Finance (April 2008 to present). He received a knighthood in 2006.

Professor Barry JA Furr OBE FMedSci FIBiol CBiol BSc MA PhD**CR** **FC**

Professor Furr (b 1943) retired as Chief Scientist and Head of the Project Evaluation Group at AstraZeneca in November 2005, but remains a part-time consultant; he also consults for a number of other companies. He has worked on cancer and reproductive biology research for over 30 years and was involved in the discovery and development of Zoladex and Casodex used in the treatment of breast and prostate cancer. He holds an honorary chair at the University of Manchester and is William Pitt Fellow at Pembroke College Cambridge. He is a Fellow of the Academy of Medical Sciences and a Fellow of the Institute of Biology. He was awarded an OBE in the Millennium Honours List for services to cancer drug discovery.

Professor Keith Gull CBE FRS FMedSci**CR** **RC**

Professor Gull (b 1948) holds a Wellcome Trust Principal Research Fellowship at the Sir William Dunn School of Pathology, University of Oxford. His research is focussed on molecular parasitology, particularly African trypanosomiasis. He has served on numerous research committees of funding agencies and charities, has been a member of the BBSRC Council and of the Committee for Safety of Medicines, was Chairman of the Biochemical Society (1998-2001), and is a member of the Leverhulme Trust's Research Awards Advisory Committee. He is a Fellow of the Academy of Medical Sciences and a Fellow of the Royal Society and was awarded a CBE in the 2004 New Year Honours list.

Liz A Hewitt FCA BSc(Econ) FRSA**AC** **FC**

Liz Hewitt (b 1956) has been Group Director of Corporate Affairs for Smith & Nephew plc, the global medical technology business, since 2004. Liz is a Fellow of the Institute of Chartered Accountants in England and Wales, having qualified with Arthur Andersen & Co. She has worked for ten years in the venture capital industry for Gartmore Investment Limited, Citicorp Venture Capital Limited and 3i Group plc. In 2003, Liz was seconded by 3i to the Department of Trade and Industry and HM Treasury, where she worked on an SME financing programme which was announced in the Chancellor's Autumn Statement in 2003. Liz's charitable work has included non-executive roles with the Rail Users Consultative Committee, Bournemouth NHS Trust, Vice-Chairman of the Surrey Police Authority and the Audit and Finance Committee of the Royal Society of Arts.

Dame Bridget Ogilvie AC DBE FRS**CR** Chair **HR**

Dame Bridget (b 1938) obtained her doctoral degrees from the University of Cambridge for research in parasitology. Before joining the Wellcome Trust in 1979, she was a member of the scientific staff of the National Institute for Medical Research. She was Director of the Wellcome Trust between 1991 and 1998. Dame Bridget occupies herself with a variety of non-executive roles.

Dr Keith F Palmer

FC Chair AC CR NG RC

Dr Palmer (b 1947) is currently Chairman of Barts and the London NHS Trust and Trustee of the Barts and the London Charitable Foundation. He is also Chairman of Cambridge Economic Policy Associates and Chairman of Infraco Ltd. He held senior positions with Rothschild from 1984 to 2002 and prior to that he worked at the World Bank and as a resident advisor to governments of Papua New Guinea and Tanzania. He is a part-time Professor at the University of Dundee, a non-executive of IVIMEDS, an international medical education collaboration, a Trustee of Kirkhouse Trust and a Senior Associate of the King's Fund. He is a Trustee of Imperial Cancer Research Fund.

Anthony H Percival FCA

AC Chair FC

Tony Percival (b 1940) is a Chartered Accountant and a former Partner of PricewaterhouseCoopers. He was an Executive Director of Kingfisher plc, having been Group Finance Director from 1995 to 1999, and is a non-Executive Director of the Royal London UK Equity and Income Trust plc and Gatekeeper Systems Inc. He is a Director of Cancer Research UK Trading Limited and is a Trustee and Chairman (Designate) of Imperial Cancer Research Fund.

Timothy SD Pile

FC FM Chair

Tim Pile (b 1953) is currently CEO of Cogent Elliott Group, a large Midlands-based marketing consultancy. Previously Tim was Chief Executive Officer of Sainsbury's Bank, an independent plc owned by J Sainsbury and HBOS, set up as a joint venture in 1997. From 1996 to 2001 Tim was with the Alliance and Leicester Group as Business Strategy & Marketing Director. He worked for Lloyds TSB as Marketing Director between 1992 and 1996 and on various marketing and industry bodies and is an Honorary Senior Fellow of Birmingham Business School and a Governor of Bromsgrove School. He was a Trustee of the Cancer Research UK Pension Fund until 1 April 2008.

Leah J Sowden FCA CTA

AC

Leah Sowden (b 1960) is a general practice partner in Saffery Champness, Chartered Accountants, based in their High Wycombe office, offering a wide range of services to businesses and charities. Leah provides audit and value added services to her charity clients. She qualified with Armitage and Norton specialising in audit and accountancy services. Previously, she served on the Charity's Audit Committee from 2002 until 2004.

Sir Kenneth R Stowe GCB CVO MA

RC Chair HR NG

Sir Kenneth Stowe (b 1927) worked in central government until 1987, holding positions including Under Secretary Cabinet Office, Principal Private Secretary to successive Prime Ministers, Permanent Under Secretary of State Northern Ireland Office and then Permanent Secretary Health and Social Security. After this Sir Kenneth was an advisor on public service reform for the UK and mainly African governments, and the UN. He was also a Trustee of various charities including the Carnegie UK Trust, The Cancer Research Campaign and CHASE Children's Hospice. He is a Fellow of the Institute of Cancer Research (ICR) and was a Trustee and Chairman of the ICR between 1987 and 1997, and a Director of the Royal Marsden Hospital. In 1998 he led the voluntary sector team in negotiating the Compact between central government and the voluntary sector, and was its co-signatory with the Home Secretary.

Professor Jeffrey Tobias MD FRCP FRCR

CR FM HR NG

Professor Jeffrey Tobias (b 1946) qualified in Medicine in 1971 and has been a cancer specialist for almost 30 years. Currently a consultant at UCL hospitals, with a personal Chair in Cancer Medicine at UCL Medical School, he previously worked at the Harvard Medical School and London's Hammersmith, St. Bartholomew's, and Royal Marsden hospitals. He trained both in medical oncology and radiation therapy, the major non-surgical treatments for cancer. His publications include *Cancer: What Every Patient Needs to Know* and *Living with Cancer*, both written for the general public (the latter to accompany a major BBC television series), as well as a large number of original research papers in breast, gynaecological and head-and-neck cancer. He has also written widely on ethical issues (including consent) in cancer research. For ten years he chaired the Cancer Research Campaign breast cancer studies 'think tank'. He also previously chaired the Cancer Research Campaign (CRC) Education Committee, the Cancer Research UK Tobacco Advisory Group and was previously President of the British Association of Head and Neck Oncologists. He was the founding Secretary of the British Oncological Association and his major research interests are in novel treatments for breast cancer. He is Medical Advisor for the Current Medicine Group (CMG).

Council Committees

- AC Audit Committee
- CC Chairman's Committee
- CR Council Research Strategy Committee

- FC Finance Committee
- NG Nomination and Governance Committee
- RC Remuneration Committee

Advisory Committees

- FM Fundraising and Supporter Marketing Advisory Committee
- HR Human Resources Advisory Committee

Dr Harold Varmus MD

● CR

Harold Varmus (b 1939), former Director of the National Institutes of Health and co-recipient of a Nobel Prize for studies of the genetic basis of cancer, has served as the President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center in New York City since January 2000. Much of Dr Varmus' scientific work was conducted during 23 years as a faculty member at the University of California, San Francisco, where he and Dr J. Michael Bishop and their co-workers demonstrated the cellular origins of the oncogene of a chicken retrovirus. This discovery led to the isolation of many cellular genes that normally control growth and development and are frequently mutated in human cancer. For this work, Bishop and Varmus received many awards, including the 1989 Nobel Prize in Physiology or Medicine. Dr Varmus is also widely recognised for his studies of the replication cycles of retroviruses and hepatitis B viruses, the functions of genes implicated in cancer, and the development of mouse models for human cancer (the focus of much of the current work in his laboratory at Memorial Sloan-Kettering Cancer Center). In 1993, Varmus was named by President Clinton to serve as the Director of the National Institutes of Health, a position he held until the end of 1999. He served on the World Health Organisation's Commission on Macroeconomics and Health, chairs the Board of Directors of the Public Library of Science and the Scientific Board of the Grand Challenges in Global Health, and works with several groups to enhance scientific activity in the developing world. He has been a member of the US National Academy of Sciences since 1984 and of the Institute of Medicine since 1991. In 1982 he was awarded the Albert Lasker Basic Medical Research Award, in 2001 the Vannevar Bush Award, National Science Foundation, and also in 2001 he was awarded the National Medal of Science. A native of Freeport, Long Island, Dr Varmus majored in English Literature at Amherst College and earned a Masters degree in English at Harvard University. He is a graduate of Columbia University's College of Physicians and Surgeons.

Trustees who retired during the year

Professor Sir David C Carter MD FRCS(Ed) FRSE
(retired 13.09.07)

Baroness Cumberlege CBE DL
(retired 31.12.07)

Dr Brendan O'Neill MA FCMA
(retired 13.09.07)

Dr Carole Rawlinson
(retired 31.12.07)

Professor Dame Nancy J Rothwell
(retired 30.04.08)

The Executive Directors who were members of the Executive Board on 30 July 2008 were as follows:

Chief Executive Officer and Chairman of the Executive Board

Harpal Kumar MA MEng MBA

Harpal joined Cancer Research Technology Limited (CRT) as Chief Executive in October 2002 to drive forward the Charity's technology transfer and early drug discovery activities. In addition to his role with CRT, he became Chief Operating Officer of the Charity in July 2004, responsible for strategic direction and day-to-day operational management, before becoming Chief Executive in April 2007. Following his training as a chemical engineer, Harpal was a healthcare consultant with McKinsey and Co. In 1992, he became Chief Executive of the Papworth Trust, a specialist charity working on rehabilitation of disabled people. From 1997, he founded and was Chief Executive of Nexan Group, a medical device company specializing in cardio-respiratory monitoring, before joining CRT. Harpal is Chairman of the Beatson Institute for Cancer Research and is a Trustee of the Institute for Cancer Research. He also serves on the Boards of the National Cancer Research Institute, the UK Clinical Research Collaboration, and the NHS Innovation Council.

Executive Board

Lilian Clark PhD MBA

Executive Director, Science Operations and Funding

Lilian was appointed Executive Director, Science Operations and Funding in August 2007. She came to Cancer Research UK from Cold Spring Harbor Laboratory, where she was Dean of the Watson School of Biological Sciences, and Executive Director of Research Operations. As Executive Director, Science Operations and Funding, Lilian is responsible for a large proportion of Cancer Research UK's science funding, ensuring that assessment of applications is carried out objectively and impartially, and that the research we fund is regularly peer reviewed. This includes research both at core-funded institutes as well as grant-funded research. Lilian is also responsible for Research Services.

Professor Peter Johnson MA MD FRCP

Chief Clinician

Peter has been Chief Clinician for Cancer Research UK since January 2008. He has responsibility for the strategy and shape of the Charity's clinical activities, both in clinical research and in the wider context of cancer prevention, diagnosis and treatment. His main research interests are in immunology, particularly the use of novel antibody treatments, and in lymphoma, where he is responsible for several national and international trials and is Chair of the National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group.

Professor Sir David Lane FRS FRSE**Chief Scientist**

David is the Chief Scientist of Cancer Research UK. He is the Director of the Cancer Research UK Transformation Research Group at the University of Dundee and Chair of Singapore's Biomedical Research Council. Sir David set up his own laboratory with Cancer Research Campaign (CRC) funding at Imperial College, London, then moved to the Imperial Cancer Research Fund laboratories at Clare Hall before moving in 1990 to Dundee to help establish the CRC laboratories there. He is best known for his discovery of the p53 protein while working as a Post Doctoral Fellow at the Imperial Cancer Research Fund Laboratories at Lincoln's Inn Fields. In 1996 Sir David founded Cyclacel Pharmaceuticals Limited, now a Nasdaq-listed biotechnology company.

Christine Lloyd BSc MA ACIS MIPD FRSA**Executive Director, People and Organisational Development**

Christine is Executive Director, People and Organisation Development. Before joining Cancer Research UK in May 2005, Christine worked for Nokia as the Global Vice President of Organisation Development where she focused on business development and culture change. During her career, Christine has worked in a range of industry sectors and functional areas including Leadership Development, Human Resource Management, Organisational Change and Systems Development.

Sarah Lyness MA**Executive Director, Communications and Information**

Sarah joined Imperial Cancer Research Fund in 1997 and, at merger, developed and launched the Cancer Research UK brand, building it to be the strongest and most loved UK charity brand. She is responsible for informing and engaging with external audiences about cancer and the work of Cancer Research UK. This includes shaping and promoting the brand, the Charity's media and internet presence, as well as providing information services to patients and the public on cancer.

Professor Herbie Newell MIBiol PhD**Interim Executive Director, Clinical and Translational Research and Research Strategy**

Herbie was appointed Director of Translational Research at Cancer Research UK in 2006 and Interim Executive Director, Clinical and Translational Research and Research Strategy (CTRARS) in 2007. He is Professor of Cancer Therapeutics at the University of Newcastle upon Tyne, and past Chairman of the British Association for Cancer Research and the Laboratory Research Division of the European Organisation for Research and Treatment of Cancer (EORTC). Professor Newell was involved in the development of the licensed agents carboplatin (Paraplatin) and raltitrexed (Tomudex) and is currently working on the development of molecularly-targeted anti-cancer drugs.

Lynne Robb**Chief Financial Officer and Executive Director, Corporate Resources**

Lynne joined Cancer Research UK as Finance Director during its merger in 2002. Soon after joining she was appointed Executive Director Finance and over the last six years she has seen her role expand to Chief Financial Officer and Executive Director of Corporate Resources, which includes IS, Risk Management, Legal, Property Services, Finance, Treasury and Procurement for the whole organisation. She qualified as a chartered accountant in 1989 with Arthur Andersen & Co., after which she moved to Tate & Lyle Plc in their Group Finance team. Her career expanded over 13 years, being Finance Director of their sugar and molasses trading divisions and spending her last two years there as Integration Director, reporting directly to the CEO.

Richard C Taylor**Executive Director, Fundraising and Supporter Marketing**

Richard joined Imperial Cancer Research Fund in April 1998 as Retail Director following a career in commercial retail including Boots the Chemist, Burton menswear and the Early Learning Centre where he was responsible for all stores in the UK and Europe. Richard was appointed to his current position in 2007 following three years as Co-Director of Fundraising and Marketing. He is responsible for the five-year fundraising strategy which drives income to support the Charity's long term ambitions. Within his current responsibility he oversees 45,000 volunteers, 500 shops, 1,000 voluntary committees, a fundraising programme with 6 million registered supporters and a fundraising team of 2,100 staff. Externally, Richard is a Trustee for two other charities: Willows Counselling Service and the Neurofibromatosis Association.

Company Secretary

Rosanna Roughley LLB Solicitor

Bankers

Royal Bank of Scotland, Aldwych Branch,
Connaught House, 65 Aldwych, London WC2B 4EJ

Lloyds TSB Bank plc, Pall Mall St James's,
8/10 Waterloo Place, London SW1Y 4BE

Auditors

PricewaterhouseCoopers LLP,
80 Strand, London WC2R 0AF

Solicitors

Withers LLP, 16 Old Bailey, London EC4M 7EG